Metastatic RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective Analysis of a Single Institution

被引：0
|
作者：
Ribeiro, M. [1 ]
Gongora, A. [1 ]
Oliveira, L. [1 ]
Alessi, J. V. [1 ]
Saccardo, K. [1 ]
Zucchetti, B. [1 ]
Barbosa, F. [1 ]
Muniz, D. [1 ]
Shimada, A. [1 ]
De Souza, C. [1 ]
Feher, O. [1 ]
Katz, A. [1 ]
机构：
[1] Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
alectinib; RET-rearranged;
D O I：
10.1016/j.jtho.2019.08.1852
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.14-67
引用
收藏
页码：S857 / S858
页数：2
相关论文
共 50 条
  • [21] Alectinib shows potent antitumor activity against both ALK- and RET-rearranged non-small cell lung cancers
    Kodama, Tatsushi
    Tsukaguchi, Toshiyuki
    Satoh, Yasuko
    Yoshida, Miyuki
    Watanabe, Yoshiaki
    Kondoh, Osamu
    Sakamoto, Hiroshi
    CANCER RESEARCH, 2015, 75
  • [22] Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.
    Gautschi, Oliver
    Wolf, Juergen
    Milia, Julie
    Filleron, Thomas
    Carbone, David Paul
    Camidge, D. Ross
    Shih, Jin-Yuan
    Awad, Mark M.
    Cabillic, Florian
    Peled, Nir
    Van Den Heuvel, Michel
    Owen, Dwight Hall
    Kris, Mark G.
    Janne, Pasi A.
    Besse, Benjamin
    Cho, Byoung Chul
    Karp, Daniel D.
    Rosell, Rafael
    Mazieres, Julien
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] A Phase 2 Study of Cabozantinib for Patients with Advanced RET-Rearranged Lung Cancers
    Drilon, Alexander
    Somwar, Romel
    Smith, Roger
    Delasos, Lukas
    Albano, Melanie
    Van Voorthuyson, Martine
    Wang, Lu
    Rekhtman, Natasha
    Ni, Andy
    Plodkowski, Andrew
    Ginsberg, Michelle
    Riely, Gregory
    Rudin, Charles
    Ladanyi, Marc
    Kris, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S286 - S287
  • [24] Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
    Zhang, Kai
    Chen, Huajun
    Wang, Ye
    Yang, Lin
    Zhou, Chengzhi
    Yin, Weiqiang
    Wang, Guangsuo
    Mao, Xinru
    Xiang, Jianxing
    Li, Bing
    Zhang, Tengfei
    Fei, Shihong
    ONCOLOGY RESEARCH, 2019, 27 (05) : 575 - 582
  • [25] RET-rearranged non-small-cell lung cancer and therapeutic implications
    Loh, Zoe
    Mitchell, Paul
    John, Thomas
    Arulananda, Surein
    INTERNAL MEDICINE JOURNAL, 2019, 49 (12) : 1541 - 1545
  • [26] Real World Treatment Outcomes in Chinese Patients with RET-Rearranged Lung Cancer
    Yang, L.
    Liu, Z.
    Qiu, W.
    Yang, G.
    Xu, H.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S829 - S829
  • [27] Clinical Characteristics and Molecular Patterns Of RET-Rearranged Lung Cancer in Chinese Patients
    Fei, S.
    Zhang, K.
    Chen, H.
    Wang, Y.
    Yang, L.
    Zhou, C.
    Yin, W.
    Wang, G.
    Li, B.
    Zhang, T.
    Xiang, J.
    Mao, X.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1077 - S1077
  • [28] Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
    Mendoza, Luis
    ONCOLOGY REVIEWS, 2018, 12 (02) : 69 - 73
  • [29] Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers.
    Drilon, Alexander E.
    Sima, Camelia S.
    Somwar, Romel
    Smith, Roger
    Ginsberg, Michelle S.
    Riely, Gregory J.
    Rudin, Charles M.
    Ladanyi, Marc
    Kris, Mark G.
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
    Drilon, A.
    Bergagnini, I.
    Delasos, L.
    Sabari, J.
    Woo, K. M.
    Plodkowski, A.
    Wang, L.
    Hellmann, M. D.
    Joubert, P.
    Sima, C. S.
    Smith, R.
    Somwar, R.
    Rekhtman, N.
    Ladanyi, M.
    Riely, G. J.
    Kris, M. G.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1286 - 1291
12345